Patent classifications
A23V2200/322
MODIFIED MILK POWDER CONTAINING 1,5-ANHYDRO-D-GLUCITOL
A modified milk powder containing 1,5-anhydro-D-glucitol which is an effective component in vivo in an amount of 7.7 to 3,850 μg/g.
MODIFIED MILK POWDER CONTAINING 1,5-ANHYDRO-D-GLUCITOL
A modified milk powder containing 1,5-anhydro-D-glucitol which is an effective component in vivo in an amount of 7.7 to 3,850 μg/g.
Caffeine and Alpha Lipoic Acid Compositions for Enhanced Sensory Effects
A dietary supplement that comprises caffeine and alpha lipoic acid and optionally other compounds. The dietary supplement is useful for enhancing sensory effects for improvement of at least one of energy, focus, or productivity.
Caffeine and Alpha Lipoic Acid Compositions for Enhanced Sensory Effects
A dietary supplement that comprises caffeine and alpha lipoic acid and optionally other compounds. The dietary supplement is useful for enhancing sensory effects for improvement of at least one of energy, focus, or productivity.
Thixotropic α-lactalbumin hydrogels, method for preparing same and uses thereof
The present invention relates to shear-thinning α-lactalbumin hydrogels, which have a threshold and are thixotropic, to a method for preparing same and to the use thereof.
Thixotropic α-lactalbumin hydrogels, method for preparing same and uses thereof
The present invention relates to shear-thinning α-lactalbumin hydrogels, which have a threshold and are thixotropic, to a method for preparing same and to the use thereof.
FOOD SUPPLEMENT, FOR AS ADJUVANT, FOR PREVENTING VASCULAR DEMENTIA
Association comprising: dry extract of Bacopa monnieri, Astaxanthin, Vitamin E, L-theanine and dry extract of Centella asiatica for use as an adjuvant in the prevention of vascular dementia, as it is able to reduce the main modifiable risk factors of cognitive vascular impairment (VCI).
FOOD SUPPLEMENT, FOR AS ADJUVANT, FOR PREVENTING VASCULAR DEMENTIA
Association comprising: dry extract of Bacopa monnieri, Astaxanthin, Vitamin E, L-theanine and dry extract of Centella asiatica for use as an adjuvant in the prevention of vascular dementia, as it is able to reduce the main modifiable risk factors of cognitive vascular impairment (VCI).
Anaplerotic therapy of huntington disease and other polyglutamine diseases
The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.
Anaplerotic therapy of huntington disease and other polyglutamine diseases
The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.